Recombinant protein · Agonist of insulin receptor (INSR) · developed by Mannkind
Insulin Regular Human (Afrezza) is a rapid-acting inhaled human insulin that lowers blood glucose by binding the insulin receptor, stimulating peripheral glucose uptake by skeletal muscle and fat and inhibiting hepatic glucose production. It is used to improve glycemic control in patients with diabetes mellitus, and is studied in type 1 and type 2 diabetes.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 30, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05243628 | Phase 4 | Type 1 Diabetes | Completed | MNKD |
| NCT04125082 | Phase 4 | Type 2 Diabetes Treated With Insulin | Unknown | MNKD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Type 1 DiabetesType 2 Diabetes Treated With Insulin
Updated Oct 18, 2026. Something wrong or missing? Report it on the MNKD page.
See MNKD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MNKD catalysts and pipeline →